GBI Research

GBI Research provides industry-leading global business intelligence solutions. Our products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports per annum across a wide range of industries. Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. Key report types currently published by GBI Research include:

 

  • Market Intelligence Reports: premium analytical reports based on a combination of market data, company, deals and project content, industry surveys and additional primary and secondary research.
  • Benchmarking Reports: analytical reports comparing key financial indicators for the top 20 companies in a particular industry and geography.
  • Industry Outlook Reports: survey-based reports, revealing and analyzing the leading experts' opinions on the future of the industry covered.
  • Market Profiles: overview-level reports based on market, company and demographic data.
  • Pipeline Analysis Reports: reports analyzing the unmet need, market size and product pipeline for different disease indications, based on a detailed database of developmental products.
GBI Research
 

List of reports from GBI Research

< prev 1    3  4  5  6  7  8  9  10  
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
12/16/2015 | published by: GBI Research
... difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, ...  |  read more...
USD 6,995
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
12/15/2015 | published by: GBI Research
... and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, ...  |  read more...
USD 4,995
USD 464
Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation
12/1/2015 | published by: GBI Research
... survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the ...  |  read more...
USD 6,995
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
12/1/2015 | published by: GBI Research
... Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...  |  read more...
USD 4,995
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
12/1/2015 | published by: GBI Research
... of PC cases being diagnosed in patient’s over 75 years old. PC proliferates rapidly, is asymptomatic at its earliest stages and when symptoms do present themselves they are non-specific. There are currently no early detection ...  |  read more...
USD 4,995
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands
11/13/2015 | published by: GBI Research
... inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD ...  |  read more...
USD 4,995
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations
11/1/2015 | published by: GBI Research
... serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and ...  |  read more...
USD 4,995
Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth
11/1/2015 | published by: GBI Research
... men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection ...  |  read more...
USD 4,995
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
10/1/2015 | published by: GBI Research
... proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% ...  |  read more...
USD 4,995
Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation
10/1/2015 | published by: GBI Research
... exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, ...  |  read more...
USD 6,995
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
9/1/2015 | published by: GBI Research
... cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a ...  |  read more...
USD 4,995
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
9/1/2015 | published by: GBI Research
... Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a ...  |  read more...
USD 4,995
Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
8/6/2015 | published by: GBI Research
... immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended ...  |  read more...
USD 6,995
Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth
7/3/2015 | published by: GBI Research
... chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, ...  |  read more...
USD 4,995
Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation
7/1/2015 | published by: GBI Research
... human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as ...  |  read more...
USD 6,995
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
7/1/2015 | published by: GBI Research
... affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, ...  |  read more...
USD 4,995
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
7/1/2015 | published by: GBI Research
... proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade ...  |  read more...
USD 4,995
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
6/1/2015 | published by: GBI Research
... people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market. A highly active pancreatic ...  |  read more...
USD 6,995
Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
5/1/2015 | published by: GBI Research
... Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this ...  |  read more...
USD 4,995
Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
5/1/2015 | published by: GBI Research
... range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis ...  |  read more...
USD 6,995
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
5/1/2015 | published by: GBI Research
... its latest research, Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs, which provides in-depth analysis of Rheumatoid Arthritis (RA) ...  |  read more...
USD 4,995
Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
5/1/2015 | published by: GBI Research
... 84 molecules across all stages of development. GBI Research’s analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This ...  |  read more...
USD 6,995
MRI Systems Market to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies
4/2/2015 | published by: GBI Research
... Operational Efficiency, with Growth Driven by Developing Economies discusses the market, competitive landscape, and trends for three MRI systems market segments: High-field, Mid-field, and Low-field MRI systems. It provides comprehensive information on the key trends ...  |  read more...
USD 3,500
Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Asia-Pacific
4/1/2015 | published by: GBI Research
... monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: ...  |  read more...
USD 1,750
< prev 1    3  4  5  6  7  8  9  10  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!